Enoxaparin sodium
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Ischemic Stroke
Conditions
Acute Ischemic Stroke
Trial Timeline
Aug 1, 2003 → —
NCT ID
NCT00077805About Enoxaparin sodium
Enoxaparin sodium is a approved stage product being developed by Sanofi for Acute Ischemic Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT00077805. Target conditions include Acute Ischemic Stroke.
What happened to similar drugs?
20 of 20 similar drugs in Acute Ischemic Stroke were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00349180 | Phase 3 | Completed |
| NCT00077844 | Phase 2/3 | Completed |
| NCT00077805 | Approved | Completed |
| NCT00077818 | Approved | Completed |
| NCT00077753 | Approved | Completed |
Competing Products
20 competing products in Acute Ischemic Stroke